STK11 and neoplasm: Additionally, PI3K, AKT, and mammalian target of rapamycin (mTOR) inhibitors may serve as potential therapeutic options for patients with PIK3CA and PTEN mutations, whereas an mTOR inhibitor can be used as a therapeutic approach for targeting STK11- and FBXW7-deficient tumours.27–29